Manufacturer of Controlled Substances Registration: Apertus Pharmaceuticals, 3987 [2015-01306]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices
Controlled
Substance
Controlled
Substance
Schedule
Schedule
3987
DEPARTMENT OF JUSTICE
emcdonald on DSK67QTVN1PROD with NOTICES
Drug Enforcement Administration
2-(2,5-Dimethoxy-4-nitro-phenyl)
ethanamine (2C–N) (7521).
2-(2,5-Dimethoxy-4-(n)propylphenyl) ethanamine (2C–
P) (7524).
2-(4-Isopropylthio)-2,5dimethoxyphenyl) ethanamine
(2C–T–4) (7532).
MDPV
(3,4Methylenedioxypyrovalerone)
(7535).
2-(4-bromo-2,5-dimethoxyphenyl)N-(2-methoxybenzyl)
ethanamine
(25B–NBOMe)
(7536).
2-(4-chloro-2,5-dimethoxyphenyl)N-(2-methoxybenzyl)
ethanamine
(25C–NBOMe)
(7537).
2-(4-iodo-2,5-dimethoxyphenyl)-N(2-methoxybenzyl) ethanamine
(25I–NBOMe) (7538).
Methylone (3,4-Methylenedioxy-Nmethylcathinone) (7540).
Butylone (7541) ............................
Pentylone (7542) ..........................
alpha-pyrrolidinopentiophenone
(a-PVP) (7545).
alpha-pyrrolidinobutiophenone (a
-PBP) (7546).
AM–694 (1-(5-Fluoropentyl)-3-(2iodobenzoyl) indole) (7694).
Acetyldihydrocodeine (9051) ........
Benzylmorphine (9052) ................
Codeine-N-oxide (9053) ...............
Desomorphine (9055) ...................
Codeine methylbromide (9070) ....
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Methyldesorphine (9302) ..............
Methyldihydromorphine (9304) .....
Morphine methylbromide (9305) ..
Morphine methylsulfonate (9306)
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Pholcodine (9314) ........................
Acetylmethadol (9601) .................
Allylprodine (9602) .......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Alphameprodine (9604) ................
Alphamethadol (9605) ..................
Betacetylmethadol (9607) ............
Betameprodine (9608) ..................
Betamethadol (9609) ....................
Betaprodine (9611) .......................
Dipipanone (9622) ........................
Hydroxypethidine (9627) ..............
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ..................
Trimeperidine (9646) ....................
Phenomorphan (9647) .................
1-Methyl-4-phenyl-4propionoxypiperidine (9661).
Tilidine (9750) ...............................
Para-Fluorofentanyl (9812) ..........
3-Methylfentanyl (9813) ................
Alpha-methylfentanyl (9814) ........
Acetyl-alpha-methylfentanyl
(9815).
Beta-hydroxyfentanyl (9830) ........
VerDate Sep<11>2014
18:48 Jan 23, 2015
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Beta-hydroxy-3-methylfentanyl
(9831).
Alpha-methylthiofentanyl (9832) ...
3-Methylthiofentanyl (9833) ..........
Thiofentanyl (9835) ......................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Phenmetrazine (1631) ..................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
1Piperidinocyclohexanecarbonitrile (8603).
Alphaprodine (9010) .....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Isomethadone (9226) ...................
Meperidine (9230) ........................
Meperidine intermediate-A (9232)
Meperidine intermediate-B (9233)
Meperidine intermediate-C (9234)
Metazocine (9240) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Racemethorphan (9732) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
I
I
I
I
I
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
I
BILLING CODE P
Jkt 235001
[FR Doc. 2015–01300 Filed 1–23–15; 8:45 am]
PO 00000
Frm 00048
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Apertus
Pharmaceuticals
ACTION:
Notice of registration.
Apertus Pharmaceuticals
applied to be registered as a
manufacturer of a certain basic class of
controlled substance. The DEA grants
Apertus Pharmaceuticals registration as
a manufacturer of the controlled
substance.
SUMMARY:
By notice
dated May 28, 2014, and published in
the Federal Register on June 4, 2014, 79
FR 32321, Apertus Pharmaceuticals, 331
Consort Drive, St. Louis, Missouri
63011, applied to be registered as a
manufacturer of a certain basic class of
controlled substance. No comments or
objections were submitted to this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Apertus Pharmaceuticals to
manufacture the basic class of
controlled substance is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of Remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
small quantities of the listed controlled
substance to make reference standards
for distribution to their customers.
On March 27, 2014, Apertus
Pharmaceuticals withdrew its request
for the addition of Alfentanil (9737),
Sufentanil (9740), and Fentanyl (9801)
to this registration.
SUPPLEMENTARY INFORMATION:
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01306 Filed 1–23–15; 8:45 am]
BILLING CODE P
Fmt 4703
Sfmt 9990
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 80, Number 16 (Monday, January 26, 2015)]
[Notices]
[Page 3987]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01306]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Apertus
Pharmaceuticals
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Apertus Pharmaceuticals applied to be registered as a
manufacturer of a certain basic class of controlled substance. The DEA
grants Apertus Pharmaceuticals registration as a manufacturer of the
controlled substance.
SUPPLEMENTARY INFORMATION: By notice dated May 28, 2014, and published
in the Federal Register on June 4, 2014, 79 FR 32321, Apertus
Pharmaceuticals, 331 Consort Drive, St. Louis, Missouri 63011, applied
to be registered as a manufacturer of a certain basic class of
controlled substance. No comments or objections were submitted to this
notice.
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823(a) and determined that the registration of
Apertus Pharmaceuticals to manufacture the basic class of controlled
substance is consistent with the public interest and with United States
obligations under international treaties, conventions, or protocols in
effect on May 1, 1971. The DEA investigated the company's maintenance
of effective controls against diversion by inspecting and testing the
company's physical security systems, verifying the company's compliance
with state and local laws, and reviewing the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of Remifentanil (9739), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture small quantities of the listed
controlled substance to make reference standards for distribution to
their customers.
On March 27, 2014, Apertus Pharmaceuticals withdrew its request for
the addition of Alfentanil (9737), Sufentanil (9740), and Fentanyl
(9801) to this registration.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01306 Filed 1-23-15; 8:45 am]
BILLING CODE P
